Clinical trials
Acute Leukemia clinical trials
Below are recruiting acute leukemia clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03589729RecruitingPhase 2
Dexrazoxane to help protect the heart during blood-cancer chemo
This Phase 2 study tests dexrazoxane, a heart-protecting medicine, to reduce heart side effects from chemotherapy in people with certain blood cancers. If you qualify, you would receive dexrazoxane along with chemotherapy, and the team will monitor your heart function closely.
Houston, TexasAges 12 years+ - NCT04256317RecruitingPhase 2/Phase 3
Azacitidine pills with or without venetoclax for certain blood cancers
This study tests whether a pill form of azacitidine (ASTX030) helps people with myelodysplastic syndromes (MDS), CMML, or AML. Some groups may also receive venetoclax; the goal is better blood cancer control for people who aren’t good candidates for intensive chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT05660473RecruitingPhase 2
Study of venetoclax plus chemotherapy for Ph-negative ALL
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
TianjinAges 14–60 - NCT06111612Recruiting
Intensive chemo before stem cell transplant for myeloid cancers with spread outside marrow
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06377579Recruiting
Observational study of ivosidenib use in France for AML
This study looks at patients with a specific type of AML (IDH1 R132 mutation) who received the drug ivosidenib through a compassionate use program in France. It aims to understand how well the drug works and how it's used in real-world practice.
AmiensAges 18 years+ - NCT06439199Recruiting
Blood protein study in non-intensive chemotherapy for AML and MDS
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Nantes, Loire-AtlantiqueAges 18–99 - NCT06778187RecruitingPhase 2
Oral arsenic therapy for TP53-mutated blood cancers
This trial tests a combination of oral medications, including arsenic trioxide, venetoclax, and a chemotherapy agent (azacitidine or decitabine), for people with certain blood cancers (AML, MDS, or CMML) that have a TP53 gene mutation. The goal is to see if this pill-based treatment can help control the cancer.
Hong KongAges 18 years+ - NCT07514936RecruitingPhase 2
Venetoclax-Azacitidine With Chidamide and CAG for Older AML Patients
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
Beijing, None SelectedAges 60–75 - NCT06890494RecruitingEarly Phase 1
BiTE-EV for relapsed or hard-to-treat B-cell leukemia
This trial tests a new immunotherapy drug called BiTE-EV for people with B-cell acute lymphoblastic leukemia that has come back after treatment or is not responding well. The drug is designed to help your immune system find and kill cancer cells.
BeijingAges 18–70 - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
Birmingham, AlabamaAges 12 years+ - NCT07205315RecruitingEarly Phase 1
Testing GT801 cell therapy for blood cancer and AIHA
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Zhengzhou, HenanAges 18–75 - NCT04024761RecruitingPhase 1
NK cell therapy for leukemia relapse after transplant
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
Boston, MassachusettsAges 12 years+ - NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B-cell cancers
This early-phase trial tests a new treatment called CLIC-2201 for people whose B-cell lymphoma or leukemia has not responded to other treatments or has come back. It aims to see if this therapy can help when other options have failed.
Calgary, AlbertaAges 1 year+ - NCT06237192Recruiting
Treatment for adults with Ph-negative ALL
This trial tests a less intensive but continuous treatment approach for adults newly diagnosed with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to improve outcomes by using minimal residual disease (MRD) to guide therapy.
MoscowAges 18–55 - NCT06532084RecruitingPhase 2
Sorafenib to prevent relapse after stem cell transplant
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Saint PetersburgAges 18–75 - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT04935684RecruitingPhase 2
Fecal transplant after bone marrow transplant to improve gut health
This Phase 2 study tests whether a fecal microbiota transplant (a processed transplant of gut bacteria) after an allogeneic bone marrow transplant is safe and helpful. Participants may benefit by improving recovery in the gut microbiome during the post-transplant period.
AmiensAges 18 years+ - NCT03680677Recruiting
Checking frailty to guide treatment in older blood cancer patients
This study checks “frailty” (how strong and able you are to function) to help choose better treatment for people age 60+ with certain blood cancers like acute leukemia or MDS. It may help clinicians tailor care before major treatments like transplant or CAR T-cell therapy.
Philadelphia, PennsylvaniaAges 60 years+ - NCT07188740RecruitingPhase 1
Metformin to target leukemia-related mutation during remission
This trial tests if metformin can reduce a specific mutation (DNMT3A R882) in people with acute leukemia who are in remission. The goal is to see if it helps prevent relapse.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT04187105RecruitingPhase 2
Total marrow radiation using a targeted intensity plan before transplant
This Phase 2 study tests a more precise type of whole bone-marrow radiation before a stem cell transplant. It may help patients with certain high-risk blood cancers by preparing the body for transplant more safely and effectively.
Chicago, IllinoisAges 18–75 - NCT07278882Recruiting
Mobile app support for home maintenance therapy in childhood leukemia
This trial tests whether using a mobile app to track daily medication and weekly blood tests can help children with acute lymphoblastic leukemia (ALL) continue maintenance therapy safely at home, without needing to stay in the hospital.
Tianjin, Tianjin MunicipalityAges Up to 16 years
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute leukemia?
- Yes. Clin2 currently lists 942 recruiting acute leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.